Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Core Viewpoint - The Invesco Biotechnology & Genome ETF (PBE) offers investors a low-cost, diversified exposure to the Healthcare - Biotech sector, making it an attractive option for long-term investment [1][2]. Fund Overview - PBE was launched on June 23, 2005, and has accumulated assets of over $227.18 million, positioning it as an average-sized ETF in the Healthcare - Biotech segment [3]. - The ETF aims to replicate the performance of the Dynamic Biotechnology & Genome Intellidex Index, which evaluates companies based on various investment criteria [4]. Cost Structure - The annual operating expenses for PBE are 0.58%, which is competitive within its peer group, and it has a 12-month trailing dividend yield of 0.25% [5]. Sector Exposure and Holdings - PBE has a significant allocation in the Healthcare sector, comprising approximately 99.8% of its portfolio [6]. - The top holdings include Illumina Inc (5.81% of total assets), Alnylam Pharmaceuticals Inc, and Royalty Pharma Plc, with the top 10 holdings accounting for about 47.68% of total assets [7]. Performance Metrics - As of July 29, 2025, PBE has experienced a year-to-date loss of about 0.77% and a decline of approximately 6.82% over the past year [8]. - The ETF has traded between $56.005 and $72.238 in the past 52 weeks, with a beta of 0.76 and a standard deviation of 21.33% over the trailing three-year period, indicating a higher risk profile [8]. Alternatives - PBE carries a Zacks ETF Rank of 3 (Hold), suggesting it is a viable option for investors seeking exposure to the Healthcare ETFs sector [9]. - Other alternatives include the SPDR S&P Biotech ETF (XBI) and the iShares Biotechnology ETF (IBB), with assets of $4.78 billion and $5.53 billion respectively, and lower expense ratios of 0.35% and 0.45% [10].